OPM Announces Protocol Submission for Its Phase Ib/IIa Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1

Oncodesign Precision Medicine (OPM) announced the submission to Swiss authorities of the study protocol for its Phase Ib/IIa clinical trial REVERT with OPM-101, its RIPK2 inhibitor in advanced melanoma patients with resistance to anti-PD-1.